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Background. Novel therapies need to be evaluated in a relevant large animalmodel thatmimics the clinical course and treatment in a
reasonable time frame. To reliably assess therapeutic efficacy, knowledge regarding the translationalmodel and the course of disease
is needed. Methods. Landrace pigs were subjected to a transient occlusion of the proximal left circumflex artery (LCx) (𝑛 = 6) or
mid-left anterior descending artery (LAD) (𝑛 = 6) for 150min. Cardiac function was evaluated before by 2D echocardiography or
3D echocardiography and pressure-volume loop analysis. At 12 weeks of follow-up the heart was excised for histological analysis
and infarct size calculations. Results. Directly following AMI, LVEF was severely reduced compared to baseline in the LAD group
(−17.1±1.6%, 𝑃 = 0.009) compared to only amoderate reduction in the LCx group (−5.9±1.5%, 𝑃 = 0.02) and this effect remained
unchanged during 12 weeks of follow-up. Conclusion. Two models of chronic MI, representative for different patient groups, can
reproducibly be created through clinically relevant ischemia-reperfusion of the mid-LAD and proximal LCx.
1. Introduction
The treatment of patients suffering from myocardial
infarction (MI) is aimed at the preservation of cardiac
function. Most treatment regimens directly target pathways
that limit infarct size or reduce adverse remodeling, thereby
preventing progression into heart failure (HF) [1–3]. To fully
determine the possible effect of such therapies, thorough
testing in clinically relevant animal models is needed [4, 5].
Since large animalmodels enable clinical treatment regimens,
delivery route, and identical function-related measurements,
they are considered to withhold greater translational value
than small animal models and are therefore superior for
efficacy testing [6–10].
Importantly, due to optimized logistical and diagnostic
health care, the complaint-to-needle time has decreased
considerably in the western world [11]. This has resulted in
a large proportion of patients with a relatively preserved
left ventricular function after MI [12]. These patients could,
however, still benefit from therapy that further confines the
amount of damage directly after MI. To test the efficacy
of such therapies, an animal model that closely resembles
the clinical course of disease in a mildly damaged heart
is mandatory. At the same time, therapy optimization has
also resulted in an increased incidence of HF, since patients
survive with severely deteriorated cardiac function [13].
This patient group would greatly benefit from therapy that
improves cardiac function. For this purpose, an animalmodel
that closely resembles the progression into HF after MI in
patients with a severely damaged heart is needed.
To create both a moderate and a severe model of chronic
myocardial infarction that resemble these different patient
groups, ischemia can be induced in several ways. These
include permanent ligation, progressing occlusion by place-
ment of ameroid constrictors, a bottleneck stent model, and
coiling or infusion of ethanol in the target coronary artery
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[14–18]. However, most of thesemodels do notmimic current
clinical reality, where most patients are revascularized within
relatively short time after occlusion. Since revascularization
of the target vessel remains the cornerstone treatment in
MI patients, animal models have to simulate this situation,
even more so since myocardial wound healing and other
molecular mechanisms are substantially different after revas-
cularization compared to those during persistent ischemia
[19, 20]. Moreover, the chronic coronary occlusion precludes
intracoronary infusions, the easiest and fastest technique
for myocardial delivery of therapeutics. Hence, models of
ischemia/reperfusion, in which coronary flow is restored
after an ischemic period, seem most suited to validate novel
therapies for the treatment of MI.
In most ischemia/reperfusion models, the left anterior
descending artery (LAD) is occluded, which is associated
with a high mortality rate during infarct induction and
reperfusion due to ventricular fibrillation (VF) [8, 21]. As
an alternative for LAD occlusion, the left circumflex artery
(LCx) can be occluded. The LCx is responsible for approxi-
mately 20% of the blood supply to the left ventricle and an
occlusion-reperfusion model of this artery may result in a
lower mortality rate [21]. However, it is not fully elucidated
to what extent animals that are subjected to LCx ischemia-
reperfusion develop cardiac dysfunction during long-term
follow-up. Moreover, no thorough sequential investigation
of cardiac (dys) function and ventricular dilatation has been
performed in either model to the best of our knowledge.
Therefore, this study was designed to investigate the long-
term effect of myocardial infarction on cardiac function in
two clinically relevant large animal models of MI: a severe
mid-LAD ischemia-reperfusionmodel and amoderate prox-
imal LCx ischemia-reperfusion model. In the present study
we investigated the course of both global and regional cardiac
function decay in the two models combined with mortality,
infarct size, and histological analysis.
2. Objectives
To determine the long-term course of cardiac function in
a moderate LCx and a severe LAD ischemia-reperfusion
model for future validation of novel therapeutic strategies,
we hypothesized that LAD ischemia-reperfusionwill result in
fast development of cardiac dysfunction representing a good
model for severely affected patients with cardiac dilatation
and signs of heart failure. Secondly, we hypothesized that
the LCx ischemia-reperfusion model leads to a moderately
affected heart representing a large patient group that has been
adequately revascularized after an initial ischemic event but
could still benefit from additional therapy.
3. Material and Methods
All procedures were approved by the local animal welfare
committee of the University of Utrecht (Utrecht,The Nether-
lands; Permit number 2011.II.04.068). A total of 12 female
specific pathogen free (SPF) landrace pigs were included
(65.1 ± 1.0 kg; van Beek, Lelystad, The Netherlands). The
pigs were housed in the experimental animal facility at
the University of Utrecht (Utrecht, The Netherlands) in a
group prior to procedure and individually after the AMI (to
prevent hostile behavior after infarct procedure).The animals
were checked by a veterinarian upon arrival at the facility
and daily scored by a biotechnician and once a week by a
veterinarian during follow-up. Six animals were randomized
to undergo ischemia-reperfusion of the LCx and 6 animals
were randomized to undergo LAD ischemia-reperfusion.
3.1. Medical Treatment before Infarct Induction. All ani-
mals received dual antiplatelet therapy (acetylsalicylic acid
80mg/d: Ratiopharm, Haarlem, The Netherlands; clopido-
grel 75mg/d: Apothecon, Barneveld, The Netherlands) and
antiarrhythmic drugs (Amiodarone, 1200mg loading dose,
800mg qd, Sanofi-Aventis, Paris, France) starting 10 days
prior to infarct induction up until sacrifice at 12 weeks of FU.
3.2. Anesthesia Protocol. General anesthesia was induced
with an intramuscular injection of 0.5mg/kg midazolam
(Actavis, Zug, Switzerland), 10mg/kg ketamine (Narketan,
Ve´toquinol, Lure Cedex, France), and 1mg of atropine
(Pharmachemie BV, The Netherlands) and maintained with
intravenous infusion of midazolam 0.5mg/kg/h, sufentanil
2.5 𝜇g/kg/h (Janssen-Cilag BV, Tilburg, The Netherlands),
and pancuronium 0.1mg/kg/h (Inresa, Battenheim, Ger-
many). Upon infarct induction, all animals were ther-
apeutically heparinized with 2 doses of 5000 IE (Leo
Pharma, Ballerup, Denmark). All pigs received a fentanyl
patch (25mg, Janssen-Cilag, Tilburg, The Netherlands) and
meloxicam (Boehringer-Ingelheim, Alkmaar, The Nether-
lands) 0.5mg/kg/d, as postsurgery analgesia.
3.3. Infarct Procedure. Animals were randomized before the
start of the procedure via sealed envelopes. Cardiac function
at baseline was quantified by 2D echocardiography and
pressure-volume (PV) loop analysis. Blood was sampled
before AMI and 6 hours after for troponin I analysis.
All animals received a Reveal event recorder (Medtronic,
Tilburg, The Netherlands).
3.4. Balloon Occlusion of the LCx. An 8F sheath was inserted
in the carotid artery and an 8F guiding catheter (JL 3.5–4.0,
Boston Scientific Nederland BV, Nieuwegein, The Nether-
lands) was positioned at the ostium of the left main coronary
artery. An angioplasty balloon (Trek 3.5–4.0 ×12, Abbott)
was inflated (8–14 bar) for 150min in the proximal LCx
(Figure 1). After balloon inflation, the guiding catheter was
carefully retracted to enable normal blood flow through the
nonoccluded part of the left coronary system. Position was
verified every 15 minutes to ensure appropriate occlusion of
the LCx. After the procedure catheters were removed and the
wound was closed.
3.5. Open Chest Ligation of the LAD. An anteroseptal
myocardial infarct was induced during an open chest pro-
cedure in order to reduce periprocedural mortality due to
VF. The thorax was opened via sternotomy. The infarct was
induced by a transient ligation of the mid-LAD after the first
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Figure 1: Study design. (a) Flowchart. (b) 1: left anterior descending
artery (LAD); 2: ligation of the LAD was located after the first
diagonal branch; 3: location and example of balloon occlusion of the
left circumflex artery (LCx). BL: baseline before infarct induction;
PMI: postmyocardial infarct; w: week.
diagonal for 150min. All pigs subjected to LAD ischemia-
reperfusion underwent a 3D epicardial echocardiography
before and after infarct induction.
3.6. Follow-Up. During the 12 weeks of FU, a 2D echocar-
diography was performed at 4 and 8 weeks of FU under
induction medication as described above. Twelve weeks after
infarct induction the animals were anesthetized, and 2D and
3D epicardial echocardiography were performed followed by
invasive PV loop measurements. The animals were sacrificed
and the hearts were excised for infarct size determination and
histological analyses.
3.7. Echocardiography. Echocardiography was performed
using a Phillips iE33 echocardiography machine (Phillips,
Eindhoven, The Netherlands). 2D images were obtained
of the parasternal long axis and parasternal short axis at
basal, mid-ventricular, and apical level. The 2D echo was
repeated after infarct induction in the animals with LCx
infarction. This was not possible in the LAD group because
of fluid and air in the chest after open chest procedure.
Additionally, a 3D epicardial echocardiogramwas performed
in the LAD ischemia-reperfusion before and aftermyocardial
infarction as previously described [22]. In both groups,
animals underwent additional 2D echocardiography at 4 and
8 weeks following infarct induction, using a mild sedation of
midazolam, ketamine, and atropine as described earlier. At
sacrifice, both animals in the LCx and LAD group underwent
transthoracic 2D and epicardial 3D echocardiography.
Images were analyzed using Velocity Vector Imaging
(VVI, Siemens Medical solutions, USA). The end-diastolic
and end-systolic volumes were calculated by the modi-
fied Simpson rule (LV end-diastolic volume ((LVEDV) =
(𝐴𝑏ED) ∗ 𝐿/3 + (𝐴𝑚ED +𝐴𝑝ED)/2) ∗ 𝐿/3 + 1/3(𝐴𝑝ED) ∗ 𝐿/3;
LV end-systolic volume ((LVESV) = (𝐴𝑏ES) ∗ 𝐿/3 + (𝐴𝑚ES +
𝐴𝑝ES)/2) ∗ 𝐿/3 + 1/3(𝐴𝑝ES) ∗ 𝐿/3, in which 𝐴𝑏 is the area
at basal level, whereas 𝐴𝑚 and 𝐴𝑝 are the areas at mid and
apical levels, resp, and 𝐿 is the length of the ventricle) [23].
LVEF was calculated by ((LVEDV− LVESV)/LVEDV) ∗ 100.
3D echocardiographs were analyzed offline using Qlab
10.1 software (Phillips, Eindhoven, The Netherlands) as
described before [24]. One full volume analysis was used and
the end-diastolic frame was selected. Markers were placed
at the base of anterior, posterior, inferior, and lateral sides
and at the apex. The left ventricle was automatically traced
by the software. All frames were checked for correct tracing
and manually corrected if needed.The same was repeated for
the end-systolic phase.
3.8. Strain Analysis. Strain is defined as the total deformation
of the myocardium during 1 cardiac cycle [25, 26]. Radial and
circumferential strains were analyzed on the 2D echocardio-
graphy short axis views via speckle tracking (VVI, Siemens
Medical solutions, USA) as previously described [25]. Strain
was analyzed according to the 17-segment echocardiogra-
phy model. Figure 2 provides a schematic overview of the
radial strain and circumferential strain and the 17-segment
echocardiography model. In the LAD model anterior and
anteroseptal segments were analyzed, whereas the inferior
and inferolateral segments were used as reference segments
in this group. In the LCx group, inferior and inferolateral
segments were mostly affected and anterior segments were
used as reference segments. Moreover, global strain was
calculated by the software. Strain is represented as percentage
of left ventricular deformation.
3.9. Pressure-Volume Loop Analysis. A 7F conductance
catheter (CD Leycom, Zoetermeer, The Netherlands) was
placed under fluoroscopic guidance in the apex of the
left ventricle as previously described [27]. Pressure-volume
loops (PV loops) were assessed during apnea to avoid
pressure/volume changes due to mechanical ventilation. Cal-
ibration was performed as previously described [28]. PV
loops were performed to obtain data of systolic indices
(end-systolic pressure, stroke volume, end-systolic pressure
volume relations, stroke work, 𝑑𝑃/𝑑𝑡max, and prerecruitable
stroke work) and diastolic indices (end-diastolic pressure,
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Figure 2: Schematic overview of strain and 17-segment echocardiography model. (a) Schematic overview of strain analysis. Radial strain
represents thickening (systole, arrows outwards) and thinning (diastole, arrows facing each other) of the myocardium during 1 cardiac
cycle. Circumferential strain: elongation and shortening (arrows facing each other) of myocardial muscle fibers. (b) Schematic overview of
myocardial segments on short axis view at basal level (mitral valve level). A indicates anterior wall. AL: anterolateral wall; IL: inferolateral; I:
inferior; IS: inferoseptal; AS: anteroseptal. (c) Schematic overview of short axis view ofmyocardial segments atmid-ventricular level (papillary
muscle level). (d) Schematic view of the apex. The apex only consists of 4 segments. L indicates lateral wall.
Tau, 𝑑𝑃/𝑑𝑡 min, and end-diastolic pressure volume rela-
tions). Analyses were performed using Conduct NT analyses
software version 16.1 (CD Leycom, Zoetermeer, The Nether-
lands).
3.10. Troponin I Levels. Troponin I levels were quantified
using a standardized ELISA protocol of the clinical chemistry
laboratory of the University of Utrecht.
3.11. Infarct Size Calculations and Histological Analysis. After
the heart was excised, the atria were removed and the ven-
tricles were cut into 5 slices of approximately 1 cm thickness.
The heart was stained using 5% tetrazolium chloride solution
for 10–15 minutes at 37∘. The slices were photographed
and infarct size was calculated using automatic computer
assisted image analysis software (Clemex, Quebec, Canada)
as described before [29]. Infarct size was calculated as
percentage of the total LV area.
Biopsies were taken from the infarct area, the infarct
border zone, and the remote myocardial segments followed
by embedding into paraffin for further light microscopical
analysis. Collagen content in infarct, border, and remote
myocardial segments was assessed by trichrome stain. Briefly,
all sections were deparaffinised and fixed in Bouin’s fixative
(Sigma-Aldrich, St. Louis, USA) at 56∘ for 15 minutes. Nuclei
were stained with haematoxylin for 3 minutes. The slides
were submerged in Trichrome-AB solution for 5 minutes
after which they were treated with 0.5% acetic acid for 1
minute. Slides were mounted with Entallan (Merck, Darm-
stadt, Germany). Three random pictures were made at a
10X magnification and collagen content was calculated as
percentage collagen of total surface area using automated
analysis software (Clemex, Quebec, Canada).
Arteriole density was quantified in infarct, border, and
remote myocardial segments, using alpha smooth mus-
cle actin immunohistochemistry analysis (SMA, clone 1a4,
Sigma-Aldrich, St. Louis, USA). Endogenous peroxidase
activity was blocked by 3% methanol/H2O2 solution for 30%
and incubated with SMA 1 : 1000 overnight. Subsequently,
the slides were incubated with secondary HRP-conjugated
goat anti-mouse antibody dilution 1 : 200 (DAKO, Glostrup,
Denmark) for 90%.All slideswere immersed inDAB solution
for 2 minutes (DAKO, Glostrup, Denmark) and mounted
with Entallan. A technician that was blinded for group
allocation took 3 random pictures at 10 times magnification.
Arterioles per field of view were counted and expressed as
number per view.
Capillary density was only assessed in border in and
remote areas, because almost all capillaries are destroyed
after AMI. All sections were deparaffinised and pretreated
with trypsin EDTA (Lonza, Verviers, Belgium). Endogenous
peroxidase activity was blocked as described above. All
slides were incubated with Isolectin B4 (Bandeiraea simpli-
cifolia Isolectin B4, Dako, Glostrup, Denmark diluted 1/50)
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Table 1: Echocardiography data.
Echocardiography LCx 𝑃 value to BL∗ LAD 𝑃 value to BL∗ 𝑃 value between groups#
LVEF baseline 56.7 ± 2.0 56.4 ± 1.5 NS
LVEDV baseline 80.8 ± 6.6 68.3 ± 3.7 NS
LVESV baseline 35.3 ± 4.3 30.1 ± 4.0 NS
LVEF PMI 50.8 ± 1.6 0.03 39.4 ± 1.6 0.009 0.02
LVEDV PMI 83.7 ± 4.3 NS 79.2 ± 5.8 NS NS
LVESV PMI 40.9 ± 1.1 NS 47.9 ± 3.7 0.01 0.09
LVEF 4 weeks 48.6 ± 1.0 0.02 40.3 ± 0.7 <0.001 0.04
LVEDV 4 weeks 88.6 ± 4.4 NS 96.5 ± 4.3 0.01 0.06
LVESV 4 weeks 45.5 ± 2.0 0.07 57.7 ± 2.8 0.01 0.03
LVEF 8 weeks 51.4 ± 1.0 NS 39.9 ± 1.0 <0.001 0.04
LVEDV 8 weeks 95.8 ± 5.9 NS 97.4 ± 7.8 0.06 NS
LVESV 8 weeks 46.5 ± 3.4 0.06 58.5 ± 5.0 0.01 0.07
LVEF 12 weeks 49.3 ± 0.8 0.06 41.7 ± 1.5 <0.001 0.004
LVEDV 12 weeks 91.4 ± 4.9 NS 104.1 ± 5.7 0.02 0.03
LVESV 12 weeks 46.0 ± 2.4 0.06 60.7 ± 4.1 <0.001 0.04
Table 1 represents all data and𝑃 values for echocardiography.The postmyocardial infarct values of the LAD study aremeasured with 3D echocardiography. LCx
indicates left circumflex artery. LAD: left anterior descending artery; LVEF: left ventricular ejection fraction; LVEDV: left ventricular end-diastolic volume;
LVESV: left ventricular end-systolic volume. BL: baseline before infarct, PMI: post myocardial infarct. ∗Repeated measures ANOVA (values compared to
baseline), #Student’s 𝑡-test.
overnight. Subsequently, the slides were immersed in DAB
solution andmountedwith Entallan. Photographswere taken
at 20X magnification and number of capillaries per mm2 was
calculated.
3.12. Statistical Analysis. All data were analyzed using SPSS
Statistics 20 (IBM statistics, Chicago, USA). All data are
presented as mean ± SEM. Comparisons between groups at
a single time point (histology, infarct size, comparison of
12 weeks of FU data) were analyzed using Student’s t-tests
or Mann-Whitney U tests. For sequential data, a two-way
repeated measures ANOVA was applied. Correlations were
analyzed by Pearson’s correlation coefficient. 𝑃 < 0.05 was
considered statistically significant.
4. Results
4.1. Mortality and Safety. All animals that underwent LCx
occlusion survived initial infarct induction (100%) compared
to 5/6 animals in the LAD group (83%; 𝑃 = NS). This animal
died of ventricular fibrillation during infarct induction,
resistant to defibrillation. Fifty percent of the animals in the
LCx group needed defibrillation during infarct induction
with an average of 7.8 times, as compared to 5/6 animals in
the LAD group with an average of 12.2 times defibrillation.
During the 12 weeks of FU period, none of the animals died
or were treated for heart failure. No ventricular arrhythmias
were recorded on the Reveal detector during the 12 weeks of
FU.
4.2. Cardiac Function by Echocardiography. Both LVEF
and LV volumes before infarct induction were comparable
between the LCx and LAD group. Post-AMI LVEF decreased
with 5.9% to 50.8 ± 1.6% (𝑃 = 0.03) in the LCx group and
with 17.1% to an average of 39.4 ± 1.6% in the LAD group (𝑃 =
0.009). Following AMI, LVESV increased with 5.6 ± 2.0mL
(𝑃 = NS) in the LCx group and with 17.8 ± 6.7mL (𝑃 = 0.01)
in the LAD group (Figure 3).There was no significant change
in LVEDV following infarct induction in either of the groups.
Table 1 depicts all cardiac dimensions in both groups.
At 12 weeks of FU, 2D echocardiography revealed a
decreased LVEF of 7.9% to 49.3 ± 0.8% (𝑃 = 0.06) in
the LCx group whereas LVEF of the LAD group declined
with 14.7% to 41.7 ± 1.5% (𝑃 < 0.001). LVESV increased
nonsignificantly in the LCx group with 10.7mL to 46.0 ±
2.4mL (𝑃 = 0.06), where the LAD group did show a
significant increase of 30.6mL to 60.7± 4.1mL (P< 0.001).No
significant dilatation as measured by LVEDV was seen in the
LCx group (+10.4mL to 91.4 ± 4.9mL, 𝑃 = 0.09). LVEDV in
pigs subjected to LAD occlusion, however, was significantly
increased during follow-up (+35.8mL to 104.1 ± 5.7mL, 𝑃 =
0.02). At 12 weeks of FU, 3D echocardiography confirmed the
2D echocardiography measurements (Figure 3). In the LCx
group, LVEF was 50.0 ± 2.4% as opposed to 39.2 ± 1.9% in
the LAD group. LVEDV in the LCx group at 12 weeks of FU
was 98.5 ± 2.9mL as compared to 126.1 ± 3.5mL in the LAD
group.
4.3. Radial andCircumferential Strain. Decreased strain indi-
cates deteriorated contractile function of the myocardium. In
the LCx group, no changes in radial strain were observed in
the infarcted inferior segment (Figure 4).
For the LAD group, radial strain was significantly atten-
uated in the anterior segment of the apex during FU and
kept progressively declining (42.8 ± 4.8% at baseline and
5.6 ± 7.7% at 12 weeks of FU; 𝑃 = 0.008; Figure 4). In
this group, total apical radial strain at 12 weeks of FU also
decreased to 20.0 ± 4.5% as opposed to 45.1 ± 4.1% at baseline
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Figure 3: Echocardiography. (a)–(c) LVEF and LV volumes on echocardiography over time. (a) Left ventricular ejection fraction (LVEF)
over time. (b) Left ventricular end-diastolic volume (LVEDV) over time. (c) Left ventricular end-systolic volume (LVESV) over time. (d)–(f)
3D echocardiography at 12 weeks of FU. (d) LVEF; (e) LVEDV; and (f) LVESV at 12 weeks of FU as measured by 3D echocardiography. LCx
indicates left circumflex artery. LAD: left anterior descending artery. (g) Example of echocardiogram at end of systole at mid-ventricular level
at 12 weeks of FU. 1 indicates a formation of scar tissue at 12 week FU. Moreover, the end-systolic diameter has been increased. (h) Example
of an echocardiogram of an animal in the LCx group at 12 weeks of FU at mid-ventricular level at the end of systole. 2 indicates the location
of the scar. No clear myocardial thinning could be observed in the Lcx model. ∗𝑃 < 0.05.
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Figure 4: Continued.
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Figure 4: Radial strain and circumferential strain. (a)–(f) Radial strain anterior and inferior segments. (a)-(b) Radial strain apex, inferior and
anterior segments per group. Strain in the anterior section of the LAD study is significantly lower during follow-up than at baseline. (c)-(d)
Radial strain mid-ventricular level, inferior and anterior segments per group. (e)-(f) Radial strain basal level, inferior and anterior segments
per group. (g)–(j) Circumferential strain. (g) Apical circumferential strain over time. (h) Circular strain at mid-ventricular level over time.
(i) Circumferential strain at basal level over time. (j) Total ventricular circumferential strain over time. LCx indicates left circumflex artery.
LAD: left anterior descending artery; BL: baseline. ∗𝑃 < 0.05 within the LAD group.
Table 2: Histological analysis.
Parameter Measure LCx LAD 𝑃 value
Collagen density infarct area % 89.2 ± 4.0 89.2 ± 4.2 NS
Collagen density border area % 5.1 ± 1.5 5.5 ± 1.3 NS
Collagen density remote area % 4.4 ± 1.1 3.0 ± 0.7 NS
Arteriole density infarct area Arterioles/view 11.2 ± 1.5 10.1 ± 1.9 NS
Arteriole density border area Arterioles/view 5.1 ± 1.1 9.2 ± 1.4 NS
Arteriole density remote area Arterioles/view 3.5 ± 0.5 5.4 ± 0.9 NS
Capillary density border area Capillaries/mm2 713.9 ± 74.3 714.4 ± 85.5 NS
Capillary density remote area Capillaries/mm2 470.5 ± 48.0 376.4 ± 37.9 NS
Overview of histological parameters. NS indicates nonsignificant difference between the groups.
(𝑃 = 0.04). The total ventricular strain at 12 weeks of FU
was significantly lower in this group at 12 weeks of FU (48.6
± 2.0% at baseline and 30.1 ± 3.8% at follow-up; 𝑃 = 0.03).
These findings corroborate with the LVEF echocardiography
data. Circumferential strain was significantly reduced in the
LAD group in the apex and at mid-ventricular level of the
heart throughout the 12 weeks of FU compared to baseline
(Figure 4).
4.4. PV Loop Analysis, Infarct Size, Troponin, and Histology.
Invasive real-time PV loop analysis was also performed
at baseline and 12 weeks of FU. 𝑑𝑃/𝑑𝑡− (relaxation of
the ventricle) and ESPVR (derivative of contractility) were
significantly decreased in the LAD group but not in the
LCx group (Figure 5). Indices of diastolic dysfunction, Tau
and tPFR (time to peak filling rate), and systolic indices
tPER (time to peak ejection rate) increased in both groups.
Troponin I levels 6 hours after infarct induction in the LCx
group were lower than in the LAD group (358.6 ± 79.9𝜇g/L
versus 560.0 ± 79.9𝜇g/L, 𝑃 = 0.02; Figure 5). Post-AMI
decrease in cardiac function and troponin levels 6 hours after
infarct correlated significantly (𝑅 = −0.763; 𝑃 = 0.028).
The average infarct size in the LAD group was significantly
higher than in the LCx group (23.4 ± 2.1% in the LAD group
versus 9.5 ± 1.7% in the LCx group, Figure 5). There were no
differences in collagen density, capillary density, and arteriole
density in all myocardial segments (Table 2). A trend towards
an increase in arteriole density was observed in the LAD
group (𝑃 = 0.09).
5. Discussion
The potential effects of novel therapeutics that confine the
damage afterMI depend on the severity of the ischemic event
[3]. To determine which patient group (e.g., moderately or
severely affected patients) benefits most from such therapeu-
tics, their efficacy has to be tested in large animal models that
resemble the clinical course and severity as closely as possible
[4, 6, 21]. Therefore, the current study investigated cardiac
function over time in two clinically relevant porcine models
of ischemia-reperfusion: a severe LADmodel and amoderate
LCx ischemia-reperfusion model. Here, we demonstrated
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Figure 5: Pressure-volume loop analysis, troponin I, and infarcts size. (a)–(e) Pressure-volume loop analysis. (a) End-systolic pressure (ESP)
is significantly lower at follow-up in the LAD group; (b) time to peak ejection rate (tPER); (c) time to peak filling rate (tPFR); (d) Tau:
relaxation constant; (e) increase in pressure over time (𝑑𝑃/𝑑𝑡+); (f) troponin I levels 6 hours after myocardial infarction are higher in the
LAD group. (g)–(i) Infarct size. (g) Example of infarct by left circumflex artery infarct (LCx) ischemia-reperfusionmodel. Viablemyocardium
is red; infarct is depicted in white (arrow). (h) Infarct size in left anterior descending artery (LAD) group is significantly higher; (i) example
of an LAD infarct. LCx indicates left circumflex artery. LAD: left descending anterior artery; BL: baseline; FU: follow-up. ∗𝑃 < 0.05.
that occlusion of 150 minutes of the LAD resulted in overt
deterioration of cardiac function and progressive cardiac
dilatation. Therefore, this model is most suitable for testing
therapeutics that focus on the prevention of adverse remod-
eling after MI in severely affected patients. On the other
hand, occlusion of the LCx resulted in limited effects on
cardiac contractility and dilatation, resembling the clinical
course of adequately revascularized MI patients with only
limited cardiac damage. Thus, this model can be used to test
compounds that reduce infarct size directly afterMI but is less
suitable for prevention of adverse remodeling.
As hypothesized, the two models showed a marked
difference in response to ischemia-reperfusion. First, in the
LCx model, none of the animals died which was, most likely,
based on fewer episodes of VF. Presumably this is due to the
involvement of the septum in the infarct area in the LAD
model combined with a smaller area at risk after occlusion
of the LCx. This difference in the area at risk also resulted
in a large difference in infarct size, which was approximately
23% of the LV in the LAD model compared to 10% in the
LCx model. In turn, the larger infarct size in the LAD model
resulted in a profound decrease in LVEF culminating in
10 BioMed Research International
adverse remodeling and cardiac dilatation. The decrease in
LVEFoccurred to a lesser extent in the LCx group and this did
not result in any cardiac dilatation after MI. In concordance
with the functional echocardiography data, myocardial strain
was decreased in the affected myocardial segments in the
LAD group, whereas strain was preserved in the affected
segments in the LCx group. To the best of our knowledge,
this is the first study that has studied myocardial strain when
comparing different MI models and these findings show that
the two models are not only different regarding the global
cardiac function but also differ on a regional contractile level.
Despite the significant differences in systolic function in the
LADgroup, no differences between the groupswere observed
regarding diastolic dysfunction. In both studies, diastolic
dysfunction worsened relative to baseline measures, which
suggests that these measurements are very robust and are not
directly influenced by infarct size or dilatation in the current
study.
In a previous study of Suzuki et al. in which the mid-
LAD was occluded for 60 minutes followed by reperfusion, a
comparable mortality (16%) and decrease in cardiac function
were observed following infarct induction [18]. However,
in that study LVEF decreased transiently and recovered
significantly at 14 days and 28 days of follow-up to 47%.
This is most likely due to the occlusion time. A 60-minute
occlusion period presumably leads to reversible cell damage,
with a large fraction of myocardial stunning/hibernation that
is known to resolve spontaneously within days to weeks [30].
In our study, LVEF did not recover during FU after the initial
decrease after MI in either model. In the LAD model this
simultaneously occurred with increased LVESV and LVEDV,
suggesting progression into heart failure. This provides a
larger therapeutic window for experimental therapies that
target adverse remodeling and prevent cardiac dilatation in
this model compared to spontaneously recovering models.
The same holds true for the LCx model. Again, therapeutic
efficacy is easier to test in a model in which outcome is not
affected by confounding factors such as spontaneous recovery
that may exceed and hence mask the therapeutic effect.
Importantly, our findings in both the LAD model and the
LCx model on cardiac function and infarct size correspond
to chronicmyocardial ischemiamodels [15, 16].This indicates
that 150-minute occlusion followed by reperfusion results in
the same amount of myocardial damage but more closely
resembles the clinical course and treatment of MI. Moreover,
in our models, intracoronary therapy to limit myocardial
damage is still possible.
Despite our best efforts, the study has some limitations.
First, we assessed cardiac function by 2D echocardiography
during follow-up and obtained 3D echocardiogram directly
after MI (LAD-model only) and at sacrifice (both models).
Due to the anatomical position of porcine ribs, it is not
possible to obtain a transthoracic 4 chamber view that
would be needed for 3D echocardiography. Although cardiac
MRI is considered the gold standard for cardiac function
and volumes, due to logistic reasons, it was not feasible to
obtain sequential cardiac MRI data in our study. We are
confident that our echocardiography data are reproducible
and depict the true cardiac function following both ischemia-
reperfusion models. Second, in one group we performed a
closed chest balloon occlusion model and in the other group
an open chest model was applied. The latter was chosen in
order to be able to perform epicardial defibrillation in the
LADmodel to improve survival in the LADmodel. Since the
studywas not designed to directly compare these twomodels,
a similar infarct induction was, however, not essential.
To conclude, the current study showed that it is feasible
to create two very distinctive models of chronic myocardial
infarction to test novel therapeutics after MI for the possi-
ble treatment of different patient groups. Reperfusion after
150min ischemia of the LAD leads to severe cardiac dys-
function and the development of heart failure over a limited
period of time, whereas ischemia-reperfusion of the LCx cul-
minates in stable, moderate cardiac dysfunction. Since these
models closely resemble the clinical course and treatment of
MI and enable intracoronary therapy administration, they
are preferable to models with persistent coronary occlusion.
This study adds to refinement of preclinical studies which
hopefully will result in improved translational medicine and
a reduction of animals needed in preclinical research.
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